RxDoctor Payments Data

Puliadi Jothikumar, MD

Internal Medicine · Turlock, CANPI 1154429108

Payments from drug & device makers

$3,338in general payments, 2019–2025

Across 155 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$742
  • Novo Nordisk$630
  • AstraZeneca$570
  • Boehringer Ingelheim$447
  • Lilly USA, LLC$217
  • Johnson & Johnson$147
  • plus $585 from 10 others

What the payments were for

  • Food & beverage$3,326100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,338 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$39,520
Medicare patients
127
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$101,707
TrulicityDulaglutide16$38,155
JanuviaSitagliptin Phosphate28$31,349
EliquisApixaban43$29,433
OzempicSemaglutide16$24,701
TradjentaLinagliptin19$16,775
XareltoRivaroxaban14$10,597
VascepaIcosapent Ethyl19$9,492
Atorvastatin Calcium466$8,043
Breo ElliptaFluticasone/Vilanterol11$4,724
Dexlansoprazole DrDexlansoprazole13$4,504
Metoprolol Succinate186$3,177
Levothyroxine Sodium183$2,898
Amlodipine Besylate194$2,053
Tamsulosin Hcl106$1,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$447$118,482115 claims
Lilly USA, LLCTrulicity$217$38,15516 claims
PfizerEliquis$45$29,43343 claims
Novo NordiskOzempic$630$24,70116 claims
Johnson & JohnsonXarelto$147$10,59714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →